Hypofractionated (HF) radiation therapy protocols have shown their effectiveness in treating prostate cancer patients [1,2]. However, these protocols require a high level of accuracy in dose delivery to allow reducing treatment margins because of an increased risk of toxicity to the surrounding organs at risk (OARs) [3]. The use of reduced clinical target volume to planning target volume (CTV-to-PTV) margins for HF versus conventional fractionated treatments has shown to lead to similar late effects between the 2 cohorts whereas early side effects were more pronounced for HF treatments [4].